ES2548030T3 - Moléculas con semividas prolongadas y usos de las mismas - Google Patents

Moléculas con semividas prolongadas y usos de las mismas Download PDF

Info

Publication number
ES2548030T3
ES2548030T3 ES10783845.0T ES10783845T ES2548030T3 ES 2548030 T3 ES2548030 T3 ES 2548030T3 ES 10783845 T ES10783845 T ES 10783845T ES 2548030 T3 ES2548030 T3 ES 2548030T3
Authority
ES
Spain
Prior art keywords
abd
seq
domain
fragment
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10783845.0T
Other languages
English (en)
Inventor
Olga Lubman
William Dall'acqua
Herren Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Application granted granted Critical
Publication of ES2548030T3 publication Critical patent/ES2548030T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Una molécula que comprende un dominio de unión a albúmina (ABD) de la proteína G de Streptococcus fusionado a un fragmento Fc de IgG de unión a FcRn, en la que la molécula que comprende el ABD fusionado al fragmento Fc de IgG de unión a FcRn tiene una semivida más prolongada que una molécula que comprende el fragmento Fc de IgG de unión a FcRn sin un ABD o que comprende el ABD sin el fragmento Fc de IgG de unión a FcRn

Description

imagen1
imagen2
imagen3
imagen4
5
15
25
35
45
55
65
E10783845
22-09-2015
Dominio de unión a albúmina (ABD)
El ABD se deriva de Streptococcus. Los dominios ABD se describen en el documento Johansson et al. (The Journal of Biological Chemistry, 277: 8114-8120, 2002).
Típicamente, el dominio ABD de la presente invención es pequeño, por ejemplo, aproximadamente 70, 60, 50, 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39, 38, 37,36, 35, 34, 33, 32, 31, 30, 28, 27 ó 26 aminoácidos de longitud y puede unirse a albúmina, tal como albúmina de suero humano. Por ejemplo, el dominio ABD puede unirse a albúmina a una afinidad de 1 mM a 1 nM. Por consiguiente, el dominio ABD de la presente invención derivado de una proteína capaz de unirse a albúmina de suero humano (por ejemplo, proteína G estreptocócica) comprenderá al menos esa parte suficiente para unirse a albúmina de suero humano (por ejemplo, SEC ID Nº 1), pero no comprenderá toda la secuencia de aminoácidos de la proteína. El dominio puede incluir, además, un haz de triple hélice tal como un haz de triple hélice levógiro. En ciertas realizaciones, el dominio ABD comprende la SEC ID Nº 1 o la SEC ID Nº 2. En otras realizaciones, el dominio ABD consta de la SEC ID Nº 1 o la SEC ID Nº 2.
La divulgación también incluye variantes de dominios ABD conocidos. Las variantes de ABD pueden contener al menos una alteración de aminoácidos, tal como una sustitución de aminoácidos conservativa en comparación con la secuencia de aminoácidos del ABD de tipo silvestre o puede incluir deleciones de aminoácidos del dominio. Las variantes de ABD pueden tener al menos el 99 %, 98 %, 97 %, 96 %, 95 %, 95 %, 94 %, 93 %, 92 %, 91 %, 90 %, 85 %, 80 %, 75 %, 70 % o 65 % de identidad de secuencia con el ABD de tipo silvestre.
Las variantes de ABD típicamente tienen la misma actividad o sustancialmente la misma actividad que los ABD de tipo silvestre. Por ejemplo, la actividad puede ser la capacidad del dominio para unirse a albúmina, por ejemplo, la variante puede unirse a albúmina con una afinidad (KD) de al menos 1 mM. Las variantes de ABD también incluyen fragmentos de ABD que conservan la capacidad de unirse a albúmina. El fragmento puede ser un dominio ABD que carece, por ejemplo, de 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 o más aminoácidos.
Los ejemplos de ABD de la presente invención incluyen:
G148-GA3: LAEAKVLANRELDKYGVSDYYKNLINNAKTVEGVKALIDEILAALP (SEC ID Nº 1)
ALB8-GA: LKNAKEDAIAELKKAGITSDFYFNAINKAKTVEEVNALKNEILKA (SEC ID Nº 2)
Se apreciará que variantes de G148-GA3 y ALB8-GA pueden tener al menos el 99 %, 98 %, 97 %, 96 %, 95 %, 95 %, 94 %, 93 %, 92 %, 91 %, 90 %, 85 %, 80 %, 75 %, 70 % o 65 % de identidad de secuencia con la SEC ID Nº1 o la SEC ID Nº2 y conservan la capacidad de unirse a albúmina de suero humano.
Las variantes de G148-GA3 y ALB8-GA también pueden incluir ABD que tienen sustituciones, deleciones o inserciones de aminoácidos de uno o más aminoácidos. En un ejemplo, el ABD tiene 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20 o más sustituciones de aminoácidos conservativas.
En un ejemplo, la divulgación incluye una variante de G148-GA3. La variante de G148-GA3 debe tener sustancialmente la misma actividad que G148-GA3 y unirse a albúmina de suero humano con aproximadamente la misma afinidad. Además, la G148-GA3 debe mostrar una conformación de haz de triple hélice levógiro. Residuos críticos para la unión a albúmina están presentes en la hélice 2 e incluyen los residuos S 18, Y20 y Y21 y residuos críticos para la formación del haz de triple hélice levógiro incluyen L12, V33, 1I37 e I40. (Los residuos críticos están en negrita y subrayados a continuación.) Los residuos críticos pueden ser menos tolerantes a sustituciones de aminoácidos no conservativas, por consiguiente, mantenerlos es generalmente preferido. Sin embargo, pueden utilizarse sustituciones conservativas en residuos críticos.
LAEAKVLANRELDKYGVSDYYKNLINNAKTVEGVKALIDEILAALP (SEC ID Nº 1)
De este modo, una variante de G148-GA3 debe conservar los aminoácidos críticos y puede incluir una o más sustituciones de aminoácidos de otra forma a lo largo de la longitud de la SEC ID Nº 1 o ser un fragmento de la SEC ID Nº1.
Variantes del dominio ABD pueden ensayarse para su capacidad de unirse a albúmina de suero humano (por ejemplo tal como se perfila en el ejemplo 2). Las variantes pueden ensayarse, además, para determinar si pueden unirse al FcRn (por ejemplo, tal como se perfila en el ejemplo 3)
La invención incluye, además, las secuencias de ácido nucleico que codifican los ABD de la invención. Debido a la inherente degeneración del código genético, otras secuencias de ADN que codifican sustancialmente la misma o una secuencia de aminoácidos de funcionalidad equivalente, pueden usarse para clonar y expresar el dominio ABD.
Fragmento Fc de IgG de unión a FcRn
6
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21

Claims (1)

  1. imagen1
ES10783845.0T 2009-06-01 2010-05-28 Moléculas con semividas prolongadas y usos de las mismas Active ES2548030T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18285809P 2009-06-01 2009-06-01
US182858P 2009-06-01
PCT/US2010/036497 WO2010141329A1 (en) 2009-06-01 2010-05-28 Molecules with extended half-lives and uses thereof

Publications (1)

Publication Number Publication Date
ES2548030T3 true ES2548030T3 (es) 2015-10-13

Family

ID=43298055

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10783845.0T Active ES2548030T3 (es) 2009-06-01 2010-05-28 Moléculas con semividas prolongadas y usos de las mismas

Country Status (5)

Country Link
US (2) US20120134984A1 (es)
EP (1) EP2437767B1 (es)
DK (1) DK2437767T3 (es)
ES (1) ES2548030T3 (es)
WO (1) WO2010141329A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101722961B1 (ko) 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
EP2493921B1 (en) 2009-10-30 2018-09-26 Albumedix Ltd Albumin variants
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
CN103003296A (zh) 2010-07-09 2013-03-27 阿菲博迪公司 多肽
JP6047142B2 (ja) * 2011-04-01 2016-12-21 ウニヴェルズィテート シュトゥットガルト 抗体結合ドメインを有する組換えｔｎｆリガンドファミリーメンバーポリペプチドおよびそれらの使用
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
DK2825556T3 (en) 2012-03-16 2018-04-16 Albumedix As albumin Variants
JP2015512902A (ja) * 2012-03-28 2015-04-30 アフィボディ・アーベー 経口投与
JP2020033372A (ja) * 2012-03-28 2020-03-05 アフィボディ・アーベー 経口投与
CN104470944B (zh) * 2012-05-25 2021-09-14 詹森生物科技公司 非天然共有白蛋白结合结构域
WO2014048977A1 (en) 2012-09-25 2014-04-03 Affibody Ab Albumin binding polzpeptide
MX2015005363A (es) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.
WO2014140882A2 (en) * 2013-03-14 2014-09-18 The Governing Council Of The University Of Toronto Scaffolded peptidic libraries and methods of making and screening the same
UA118029C2 (uk) 2013-04-29 2018-11-12 Ф. Хоффманн-Ля Рош Аг Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
WO2014177459A2 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
US10167322B2 (en) 2013-12-20 2019-01-01 Affibody Ab Engineered albumin binding polypeptide
MX380658B (es) 2014-01-15 2025-03-11 Hoffmann La Roche Variantes de region fc con union mejorada de la proteina a.
JP7007261B2 (ja) 2015-08-20 2022-01-24 アルブミディクス リミティド アルブミン変異体及びコンジュゲート
AU2017234679A1 (en) * 2016-03-16 2018-08-30 Merrimack Pharmaceuticals, Inc. Engineered trail for cancer therapy
CN111164104A (zh) 2017-08-09 2020-05-15 麻省理工学院 白蛋白结合肽缀合物及其方法
US12594347B2 (en) * 2018-09-07 2026-04-07 Duke University Nanoparticulate drug delivery systems
KR102282240B1 (ko) * 2018-12-06 2021-07-28 경상국립대학교산학협력단 지속형 엑센딘-4 및 이의 용도
AU2020301529B2 (en) 2019-06-24 2026-03-26 Universität Stuttgart TNFR2 agonists with improved stability
US20230303646A1 (en) * 2020-08-19 2023-09-28 Energesis Pharmaceuticals, Inc. Analogs of human fibroblast growth factors
CN115232215B (zh) * 2021-04-23 2026-03-27 湖州芈首生物技术有限公司 一种融合蛋白ABD/Fc/IL-2及其编码基因、制备方法和应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0092918B1 (en) 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Continuous release formulations
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
CA2071867A1 (en) 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
WO1991014438A1 (en) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
CA2092323A1 (en) 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
WO1992010591A1 (en) 1990-12-14 1992-06-25 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
CA2109528A1 (en) 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
CA2103064A1 (en) 1991-05-14 1992-11-15 George Y. Wu Targeted delivery of genes encoding immunogenic proteins
DK0587738T3 (da) 1991-06-05 2000-12-18 Univ Connecticut Destineret levering af gener, som koder for sekretionsproteiner
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
EP0633943A4 (en) 1992-04-03 1997-05-02 Alexander T Young GENTHERAPY USING TARGETED VIRAL VECTORS.
ES2157225T3 (es) 1992-10-09 2001-08-16 Advanced Tissue Sciences Inc Celulas hepaticas de reserva.
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
HUT76369A (en) 1994-07-29 1997-08-28 Smithkline Beecham Corp Novel soluble protein compounds
ATE252894T1 (de) 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
EP1658772A3 (en) 1995-01-17 2007-01-17 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997007788A2 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6590079B2 (en) 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
HUP0100813A3 (en) 1998-02-25 2003-08-28 Lexigen Pharmaceuticals Corp L Enhancing the circulating half-life of antibody-based fusion proteins
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6531580B1 (en) 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
WO2003087335A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
WO2003087327A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
US20040042972A1 (en) 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
US7923029B2 (en) 2002-04-11 2011-04-12 Medimmune Llc Spray freeze dry of compositions for pulmonary administration
JP2004045384A (ja) * 2002-05-22 2004-02-12 Matsushita Electric Ind Co Ltd 免疫学的測定方法、免疫学的測定装置、生体成分測定用トイレ、抗アルブミンモノクローナル抗体、それを産生する細胞株、およびアルブミン検出キット
CN1745170A (zh) 2002-12-17 2006-03-08 米迪缪尼疫苗股份有限公司 生物活性材料的高压喷雾干燥
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
ATE536369T1 (de) * 2006-10-11 2011-12-15 Ablynx Nv Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung
US20080267949A1 (en) * 2006-12-05 2008-10-30 Ablynx N.V. Peptides capable of binding to serum proteins
EP2190863B1 (en) * 2007-07-31 2015-09-02 Affibody AB New albumin binding compositions, methods and uses
EP2535349A1 (en) * 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions

Also Published As

Publication number Publication date
US20120134984A1 (en) 2012-05-31
DK2437767T3 (en) 2015-09-28
WO2010141329A1 (en) 2010-12-09
US20140170142A1 (en) 2014-06-19
EP2437767A1 (en) 2012-04-11
EP2437767B1 (en) 2015-07-08
EP2437767A4 (en) 2013-04-03

Similar Documents

Publication Publication Date Title
ES2548030T3 (es) Moléculas con semividas prolongadas y usos de las mismas
ES2637613T3 (es) Procedimientos de purificación de polipéptidos
AR125394A2 (es) Métodos y composiciones para la expresión génica en plantas
Bate et al. Talin contains a C-terminal calpain2 cleavage site important in focal adhesion dynamics
JP2019506166A5 (es)
AR108442A1 (es) Proteínas de fusión gdf15 y usos de estas
DOP2021000197A (es) Composición farmacéutica, que comprende la variante de hialuronidasa ph20 humana y fármaco, para inyección subcutánea
ES2534040T3 (es) Plasmina modificada de forma recombinante
ATE533782T1 (de) Impfstoffe und immuntherapeutika mit codon- optimiertem il-15 und verwendungsverfahren dafür
HRP20231183T1 (hr) Optimizirani gen faktora viii
MX358725B (es) Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
AR071874A1 (es) Proteinas de dominio de armazon basadas en fibronectina multivalentes
PE20191033A1 (es) PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
ES2641373T3 (es) Uso de P3 de proteínas de fusión de bacteriófagos como agentes de unión amiloides
BR0315327A (pt) Antagonistas de il-15
RU2016145061A (ru) Профилактическая вакцина против синдрома падения яйценоскости (eds)
ES2362195T3 (es) Secuencia de mecp2 sintética para la terapia de sustitución de proteínas.
BR112021017603A2 (pt) Vírus adenoassociado (aav) mutante tendo propriedade de direcionamento para o cérebro
CN117279618A (zh) 用于靶标分子的选择性耗竭的组合物和方法
WO2022032660A1 (zh) 新型冠状病毒rbd融合蛋白
JP2020529221A5 (es)
NZ752941A (en) Frataxin expression constructs
AR127455A1 (es) Constructos de ácido nucleico, vectores víricos y partículas víricas
BR9902019A (pt) Moléculas de polinucleotìdios que codificam proteìnas de neospora.
Blocquel et al. Interaction between the C‐terminal domains of measles virus nucleoprotein and phosphoprotein: a tight complex implying one binding site